Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
Improved efficacy, faster onset, and scalable platforms drive investor interest in next-gen CNS assets New York, NY –February 10, 2026 – Market News Updates News Commentary – Novel serotonergic agonists (“NSAs”) are quickly becoming one of the more interesting stories in mental-health and neuroscience investing. In simple terms, these drugs work by activating specific […]
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLC Proven leader in late-stage clinical development, global commercialization, and capital formation across central nervous system (“CNS”) programs Appointed as Helus Pharma advances its […]
